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Abstract
Immunotherapeutic agents have been researched for many decades as an alternative treatment for cancer. Current research 
demonstrates that immunotherapy is safer than radiotherapy or chemotherapy. This is attributed to immunotherapy’s mechanism 
of utilizing the body’s own defense system, as opposed to absorbing harmful chemicals. Two forms of immunotherapy that have 
been effective in curing cancer without the added danger of chemical toxicity are PNC-27 and PNC-28. These peptides were cre-
ated by a supercomputer at SUNY Downstate Medical Center in New York in 2000. PNC-27 and PNC-28 work with the MDM2 
-P53 tumor suppressor complex. It acts as a competitive inhibitor for binding, increasing the half-life of P53 in the cell and assisting 
with the elimination of cancer cells (Sarafraz-Yazdi E, Bowne WB, et al 2010). These immunotherapy agents also have the ability 
to bind to the cell membrane and lyse the cell. The clinical trials for PNC-27 and 28 were successful, and the drug is currently in 
use outside of the United States. Although this form of immunotherapy does come with some side effects, research illustrates that 
this form of immunotherapy can be a successful strategy in eliminating the cancer and ensuring that a relapse does not occur.
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Introduction
Cancer is one of the three leading causes of death across the 
globe. Although researchers have been discovering cures for 
many diseases, the cure for cancer still eludes them. There 
are over 240 different forms of tumors that currently exist, 
and each type comes with a unique mechanism that can 
help it evade treatment. Tumors are caused by the ongoing 
replication of a cell that does not adhere to cell regulations 
for replication (Vassilev A, DePamphilis, 2017). Due to the 
fact that tumors arise from our own cells, in order to cure 
cancer, researchers have to come up with a treatment that 
exclusively destroys malignant cells, keeping the healthy cells 
intact. While there are many cures being evaluated in cur-
rent research that target all cells,PNC-27 and PNC-28 have 
the ability to target cancer cells only.
There are millions of cells in the human body. In order for 
cells to thrive, the cells need to be replicated to ensure con-
tinuity. New cells are constantly being created as old cells are 
dying. Cells are converted to tumor cells when the check-
points that are responsible for monitoring the division do not 
proceed as expected. (Chao et al., 2017) When the cell me-
tastasizes and travels to another region within the body, the 
tumor is transformed into a potentially lethal cancer.
When a cell goes through the division process, it repli-
cates all of its chromosomes and sends an identical copy 
to the new version of the cell that was formed. The pro-
cess by which this is done is called mitosis. The cell has 
three phases that ensure that cell replication is proceeding 
correctly. These three checkpoints that ensure the legit-
imacy of DNA are known as the M Phase (Mitosis), G1 
Phase (Gap 1), and the G2 Phase (Gap 2). At the G1 phase, 
the accuracy of the DNA is evaluated before proceeding. 
At G2, the chromosome duplication is assessed. (Veron, 
2017) After these checkpoints, the cell goes on to pro-
duce identical daughter cells. In a normal, healthy cell, if a 
cell does not pass these checkpoints successfully, the cell 
is destroyed. These checkpoints are the main regulators of 
replication and ensure a low rate of errors in the DNA.
The process of mitosis guarantees perpetuation of life, 
but it can prove lethal if it proceeds unchecked. Genetic 
mutation (regardless of whether it was caused by carcino-
gens or through random errors during DNA replication) 
takes place in cells throughout the lifetime of an organism 
(Ahluwalia, 2009). When one of these mutations results in 
the breakdown of cell cycle regulation, it gives rise to an 
“unregulated proliferating descendant clone of that par-
ticular cell’’ (Cooper, 2000). This clone of cells can form 
a tumor. Tumors arise with significant frequency, but most 
tumors pose slight risk to their host cell due to tumor 
cell localization. These tumors are known to be benign tu-
mors. It is generally evident when a tumor is benign since 
the cells bear a close resemblance and role comparable to 
normal cells. (Mims, et al. 2015).
One of the most significant stages in the diagnosis of 
cancer patients is the series of events leading to the de-
velopment of tumor cell invasion and metastasis. Cancer 
metastasis is the dispersion of cancer cells to tissues and 
organs outside the original site of the tumor. Once a tumor 
has left its original source, it travels and forms additional 
tumors in other organs. This process occurs in three main 
developments: invasion, intravasation, and extravasation.
Metastasis occurs due to a loss of cell to cell adhe-
sion. Initially, the malignant tumor cells isolate from the 
main mass at the original source. Subsequently, the cells 
proceed to invade the surrounding stroma. This devel-
opment causes the secretion of substances to degrade 
the basement membrane and extracellular matrix of the 
organ it has invaded (Shields JA, Shields CL, 2016). The 
secretion of substances helps express the proteins that 
mediate the control of the tumor’s motility. In addition to 
the tumor’s ability to migrate to other organs, there is a 
process called angiogenesis. The process of angiogenesis 
is necessary for the tumor to exist and keep itself satiat-
ed. Angiogenesis is the development of new blood vessels 
that aid with local diffusion. This helps the cell sustain 
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itself with nutrients, oxygen and transporting metabolic 
wastes (Nowak-Sliwinska P, 2018).
After invading other organs, the tumor then goes 
through the introversion stage. Introversion allows for 
the tumor to make pathways throughout the blood so it 
can travel through the body and settle in another location. 
The tumor networks with the endothelial cells through 
biochemical interactions. This process is regulated by a 
carbohydrate-carbohydrate reaction.
Adhesion to the endothelial cells creates more solid 
bonds to penetrate the endothelium and the basement 
membrane (More SK, Vomhof-Dekrey EE, Basson MD., et 
al 2019). Through this process, the new tumor reproduces.
As mentioned previously, the common driving force 
behind cancer is a genetic mutation, but there are many 
distinctions in how cancer can evolve. There are different 
mutations that can alter the genes standard structure and 
function. It is generally not possible to determine what 
the underlying cause of the mutations. However, research 
has linked different risk factors to an increased probabili-
ty of cancer. Carcinogens and viral or genetic factors have 
all been linked to cancer. For example, exposure to the 
environment plays a role in how genes will be transcribed. 
The atmosphere and our food contain many toxins that 
can cause mutations. UV radiation that is induced by ex-
posure to the sun without ensuring proper protection 
causes thymine dimers, which researchers believe causes 
skin cancer. Smoking is also a significant cause of cancer.
Chemicals in tobacco smoke harm the cleansing system 
that the body employs to remove toxins. Thus, smok-
ers are not as capable of handling toxic chemicals as 
those with healthy lungs and blood (O’Keeffe LM 2017). 
Moreover, smoking damages DNA, and generates potent 
carcinogens which not only affect the trachea, bronchial 
system and lungs, but also permeate the entire system.
Methods
Data was collected using ProQuest and PubMed data-
bases, and the National Library of Medicine. The images, 
graphs, and diagrams are in the research articles refer-
enced. Additional materials were found in the SUNY (State 
University of New York) Downstate research library.
Radiation Therapy Mechanism:
Treatment of cancer originally involved surgical removal 
techniques alone. Over the previous centuries, radiation 
therapy has been discovered as an alternate treatment. 
Radiation therapy treats cancer by focusing beams of in-
tense energy on a specific part of the body to eliminate 
cancer cells. Some of these forms of energy typically in-
cludes X-rays, but can also use high-energy particles or 
waves, such as gamma rays, electron beams, or protons. 
The larger the amount of energy involved in the therapy, 
the more penetration is accomplished by the ionizing ray 
into the cancer tissue (Orth M, Lauber 2014). The ioniz-
ing ray kills the cells that are actively dividing. Although 
radiation is effective for preventing division of rapidly di-
viding cells, it can cause only minimal breaks in the DNA. 
Nevertheless, these breaks stop cancer cells from repli-
cating and producing, activating their elimination. It can 
be used to shrink early stage cancer, or treat advanced 
symptoms of cancer.
Radiation therapy attempts to strike a balance by elim-
inating the harmful dividin cells and minimizing damage to 
the normal cells around the tumor site. Normal cells can 
often repair much of the damage caused by radiation. The 
majority of people with cancer receive radiation therapy 
as part of their treatment plan, along with a combination 
with other treatments.
Physicians prescribe radiation therapy to treat all forms 
of cancer, including benign tumors. Although radiation 
therapy is effective, research shows that radiation therapy 
has a large number of side effects. These include tooth 
decay, third degree skin burns, and difficulty breathing 
(Murphy, et al. 2019). Radiation therapy is rationed, and 
there is a limit to the amount of radiation people can 
safely receive. Depending on how much radiation an 
organ has received during the first round of treatments, 
the body may not have the ability to receive radiation a 
second time.
The major lethal side effect of radiation therapy is the 
relapse of the cancer. Because radiation therapy damag-
es healthy cells, these damaged cells can metastasize to 
other locations and cause a recurrence of the cancer. 
Most types of leukemia cancer, including acute myelog-
enous leukemia (AML), chronic myelogenous leukemia 
(CML), and acute lymphoblastic leukemia (ALL) are all 
forms of cancer that originate from radiation exposure. 
Myelodysplastic syndrome (MDS), a bone marrow cancer 
that may evolve into leukemia, has also been associated 
with previous radiation exposure” (Cidon,EU 2016). Not 
all cancers may return immediately after radiation thera-
py. Research shows that solid tumors take much longer to 
develop, and don’t come back quickly. Most of these can-
cers are not spotted for years after the radiation therapy 
has caused the damage, and some are diagnosed more 
than a decade later. We may be inevitably perpetuating 
the disease itself by using radiation therapy as an option.
C Hemotherapy Mechanism:
A common form of treatment that is currently in use 
is chemotherapy. Chemotherapy is a systemic treatment, 
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and travels through the bloodstream. The treatment is 
often given to the patient for a specific time, ranging from 
6 months to a year. In cases where there is no possible 
cure, chemotherapy may be given to extend the patient’s 
life, or relieve painful symptoms. The drugs are usually 
given by IV or orally. Chemotherapy has a lower probabil-
ity of damaging cells that are at rest, such as most normal 
cells. Physicians can prescribe the treatment after surgery 
was performed to remove the original tumor, in order to 
eliminate the individual cancer cells that may have metas-
tasized before they are able to form a tumor.
The mechanism of chemotherapy is to eliminate cancer 
cells by targeting different cells at different phases of the 
cell cycle in order to halt the replication. The chemother-
apy damages the genes inside the nucleus of cells, and 
attack cells that are at the point of splitting. Some dam-
age the cells while they are replicating their gene before 
they split (Johnstone RW, 2016). Some chemotherapeutic 
agents attack the DNA of the cell by adding a methyl 
group, in order to prevent them from producing addition-
al clones of the cancer cell. These are known as alkylat-
ing agents, and they attach to DNA, RNA, and proteins 
through covalent bonding.
Alkylating agents will attack at any point in the cell 
cycle. There are many types of alkylating groups, such as 
nitrogen mustards, nitrosoureas, and aziridines. The mol-
ecules bind to the DNA and change the DNAs confor-
mation. DNA is composed of a double strand, and the 
molecules may either bind two times to one strand of 
DNA (known as a “intrastrand crosslink”) or may bind 
once to both strands (called a “interstrand crosslink”)” 
(Figure 1). If the cell attempts to replicate or fix cross-
linked DNA during cell division, the DNA strands break 
(Cancer Chemotherapy and Biotherapy, 2005). This leads 
to a form of programmed cell death called apoptosis.
Another chemotherapy drug that interferes with tran-
scription and translation is a topoisomerase inhibitor. 
When the DNA double-strand helix is unwound during 
DNA replication or transcription, the adjoining DNA 
(that has not been opened yet) is wound up extremely 
tightly. The topoisomerase inhibitor produces single- or 
double-strand breaks into DNA, reducing the tension in 
the DNA strand ahead of the replication point (Figure 
2) This allows the normal unwinding of DNA to hap-
pen during replication or transcription. Inhibition of to-
poisomerase does not allow either of these processes 
to continue (Nitiss JL, 2007). Other chemotherapy drugs 
interfere with cell metabolism. This blocks off nutrients 
and oxygen supply, which causes growth arrest.
Research has shown that chemotherapy has many side 
effects. Some of these side effects include fatigue, hair 
loss, infection, fertility problems, weight loss, damage to 
lung tissue, heart problems, kidney problems, and nerve 
damage (Uzun, 2019).) Studies show that one of the pri-
mary drawbacks is that chemotherapy does not achieve 
remission. One reason is that the original treatment is 
not successful in eliminating all the cancer cells. The re-
maining cancer cells that are left in the organ grew into 
a new tumor. Another reason that chemotherapy is not 
successful in achieving remission is that some cancer cells 
have metastasized to other parts of the body and started 
forming a new tumor in the new location. Cancer cells 
may also develop a mechanism that makes it become re-
sistant to treatment when it relapses, thereby blocking a 
possible cure (Stadlr, WM, 2014).
Immunotherapy
Researchers have discovered that one of the best methods 
(Figure 1) The figure illustrates two DNA bases that are cross-
linked by a nitrogen mustard (Siddik ZH 2005
(Figure 2) Topoisomerase I and II Inhibitors (Huda W. 2016)
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for treating cancer is immunotherapy. Immunotherapy is a 
biological therapy that utilizes substances made from living 
organisms to treat cancer. Some immunotherapy treat-
ments use genetic engineering to improve immune cells’ 
cancer-fighting capabilities and are commonly referred to 
as gene therapies. Many immunotherapy treatments for 
preventing, managing, or treating different cancers can 
also be used in combination with surgery, chemotherapy, 
radiation, or targeted therapies to aid their overall effec-
tiveness (Yang, Wang, Wang, 2019).
Immunotherapy boosts the immune system’s ability to 
identify, target, and remove cancer cells. While many cells 
replicate naturally, this behavior is tightly regulated by an 
assortment of factors, including the genes within cells. 
When growth is not required at certain points, cells are 
instructed to halt growth. Cancer cells acquire defects 
that cause them to ignore these inhibitive signals, and 
their replication proceeds in an unregulated and rapid 
manner. Because cancer cells grow and behave through 
abnormal methods, this can alert the immune system of 
a potential threat, which can recognize and eliminate can-
cer cells through a process called immunosurveillance.
Immunosurveillance is an extremely effective method 
for eliminating pathogens from the body, but the process 
isn’t always successful when it pertains to cancer. Even 
though the immune system can prevent or slow cancer 
growth, cancer cells have ways to evade destruction by 
the immune system. For instance, cancer cells may have 
genetic changes that make them appear less discernible 
to the immune system, have proteins on their surface that 
turn off immune cells, or change the normal cells around 
the tumor so they interfere with how the immune system 
responds to the cancer cells (Pardoll D. 2015).
Cancer cells develop ways to evade and escape the im-
mune system, which allows them to continue to thrive 
and metastasize to other organs (Prendergast GC, Jaffee 
EM, 2007).
Therefore, immunotherapies are designed to enhance 
the cancer-fighting capabilities of immune cells and utilize 
the body’s own protective measures to fight the tumors.
NC-27 and PNC-28 Peptides
PNC-27 and PNC-28 are synthetic peptides designed to 
specifically target and destroy cancer cells. Therapeutic 
peptides have the ability to treat an extensive range 
of diseases and cancers and contain a large number of 
advantages over proteins or antibodies. They are easily 
synthesized in a lab and are not toxic to the human body. 
They are manufactured to have a very specific affinity for 
the targeted cell. PNC-27 and PNC-28 were created using 
a super computer by Dr. Matthew Pincus and Dr. Joseph 
Michl of SUNY Downstate Medical Center. The peptides 
were created with a specific fold that only interacts with 
a particular structure present on cancer cells. It can be 
administered by nebulizer, vaginal or rectal suppository 
or intravenously at the tumor site. Many patients travel 
to foreign countries to receive this treatment. PNC-27 
and PNC-28 have been used with exceptional results, 
and over 500 patients have had a high success rate with 
the drug since 2007. PNC-27 and PNC-28 peptides have 
been shown to be highly effective in specifically targeting 
a large variety of different cancers. These peptides have 
had high success rates with breast cancer, leukemia, mela-
noma, and pancreatic cancer lines. It has proven to be the 
most effective when taken simultaneously with immune 
system boosters, proper hydration, and a diet that avoids 
excess sugars and red meat.
P 53 Mechanism for PNC-27 AND PNC 28
TP53 or ‘’tumor protein 53’’ is a gene that is located on 
the seventeenth chromosome of humans. It codes for a 
protein that regulates the cell cycle and hence functions 
as a tumor suppressor. P53 has been described as “the 
guardian of the genome”, referring to its role in keeping 
the cell stable by preventing genome mutation (Uehara 
2018). TP53 has 4 domains that are responsible for acti-
vating transcription factors, tetramerization of proteins, 
recognizing DNA sequences, and checking damaged 
DNA (Sabapathy et al 2019).
The p53 tumor suppressor has a very significant role in 
growth arrest, DNA repair, and apoptosis, and it causes a 
response to different attacks on the cell. Rapid induction 
of high p53 protein levels by various stress types prevents 
inappropriate propagation of cells carrying potentially 
mutagenic, damaged DNA (Zhang et al., 2014). In normal 
cells, p53 is an extremely unstable protein that has a half-
life ranging from 5-30 minutes. The p53 protein is present 
at very low levels in the cell, due to continuous degrada-
tion. This continuous degradation is primarily regulated 
by MDM2. Research over the past decade has assigned 
MDM2 as the central controller of p53 by regulating the 
p53 tumor suppressor function (Carotenuto, 2019).
A mutation of the p53-MDM2 complex during the in-
duction of p53 can lead to the accumulation of active 
p53 in the cell (Figure 3). Consequently, p53 half-life ex-
tends from minutes to hours. This can aid p53 in stopping 
cancer. Both PNC-27 and PNC-28 were tested as agents 
that would competitively block p53 from interacting with 
HDM-2. By acting as a competitive inhibitor, the peptides 
would prolong the half-life of p53 in cancer cells. This 




Mechanism through Membrane and Affinity to HDM2
The PNC-27 and PNC-28 cancer peptides are substanc-
es that causes the death of cancer cells only. PNC-27 
and PNC-28 accomplish this due to their affinity for 
binding to a protein called HDM-2. Cancer cells have 
high levels of HDM-2 present in their cell membranes. 
(Ehsan Sarafraz-Yazdi, Wilbur B. Bowne, 2010). Dr. Ehsan 
Sarafraz-Yazdi (Sarafraz-Yazdi E et al 2015) explains in de-
tail how the PNC-27 and PNC- 28 cancer peptide mani-
fests themselves, and what their mechanisms could mean 
for progress in the field of cancer research. The study 
points out that the peptide’s mechanism hinges on the 
fact that there are formations of oligomeric pores in the 
plasma membrane of tumor cells. (American Association 
for Cancer, 2010) The oligomeric pores are present exclu-
sively in cancer cells. Additionally, the observations illustrat-
ed that PNC-27 and PNC-28 were capable of distinguishing 
between cancerous and non-cancerous cells.
In a 2009 study, researchers discovered that the ’’ 
three-dimensional structure of PNC-27’s and PNC-28’s 
p53 residues of its amino acids may be superimposable 
onto the structure for the same residues bound to HDM-
2.” This discovery alerted researchers to the fact that that 
PNC-27 and PNC-28’s could target HDM-2 in cancer cells’ 
membranes (Pincus, et al (2011)).
Upon further research, it was discovered that by “insert-
ing untransformed cells that are not prone to PNC-27 and 
PNC-28 with HDM-2 containing a localized membrane 
signal, these cells then became inclined towards PNC-27 
and PNC-28”. This research established that the PNC-27 
peptide was able to exclusively mark HDM-2 in the mem-
branes of cancer cells and destroy them through mem-
branolysis, while at the same time leaving the healthy cells 
alive (Sookraj, et al (2010). Additional research established 
that PNC-27 and PNC-28 uses the entire peptide when 
destroying cancer cells, as opposed to fragments. (Cancer 
chemotherapy and pharmacology, 2010).
“The PNC-27 peptide has an HDM-2 binding domain 
that has the same residues 12-26 of p53 and a transmem-
brane-penetrating domain (Sarafraz-Yazdi, et al, 2010). 
PNC-28 is a p53 peptide from its HDM2-2-binding do-
main (residues 17-26), which contains the penetratin se-
quence enabling cell penetration on its carboxyl terminal 
end. This domain is connected to a transmembrane-pen-
etrating sequence, also referred to as the 
membrane residency peptide (MRP). When 
p53 binds to the HDM-2 protein through the 
12–26 amino acid sequence, HDM-2 causes 
ubiquitination of p53 that targets it for pro-
teolysis in the proteasome. Both PNC-27 and 
PNC-28 peptides , which contains a sequence 
that is identical to that of PNC-27 but lacks 
the first six amino acid residues of PNC-27 
(i.e., p53 residues 17-26), are highly toxic to a 
wide variety of cancer cells with IC50 values 
that range from around 75 ug/ml (18.6 uM) to 
200 ug/ml (50 uM).” “While PNC-27 and PNC-
28 are toxic to cancerous cell, neither peptide 
affects normal cells that are in culture, even at 
the highest doses (around 500 ug/ml) tested”. 
This discovery illustrates that both peptides 
would not be toxic to the human body, in con-
trast to the effects of many chemotherapeutic 
agents (Davitt K, Babcock BD, 2014).
In a newer study that was analyzed in 
2014 and published in Annals of Clinical & 
Laboratory Science, researchers conclud-
ed that “the anti-cancer peptide, PNC-27 and PNC-28, 
induces tumor cell necrosis of a poorly differentiated 
non-solid tissue mammalian leukemia cell line that de-
pends on expression of HDM-2 in the plasma membrane 
of these cells.” (Davitt, et al (2014). Studies based on in-
formation discovered in earlier experiments illustrated 
that the PNC-27 and PNC-28 peptides were able to de-
stroy solid tissue tumor cells through the mechanism of 
binding to HDM-2 proteins in their cell membranes, an 
effect which was an effect that was different from the p53 
activity in those cells.
The scientists wanted to determine whether PNC-27 
(Figure 3) A chart of the disruption of mdm2 and the p53 complex (Hashimoto N, 
Nagano H, 2010)
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peptide would also be effective against non-solid tissue 
tumor cells (Davitt et al., 2014). Their study determined 
whether the non-solid tissue tumor cells expressed 
HDM-2 in their membranes in the first place (solid tis-
sue cells were found to do so), and find if PNC-27 could 
cause these cell’s death by the HDM-2 binding. The re-
searchers observed that these non-solid tumor cells do 
express HDM-2 in cell membranes.
They also noted that the PNC-27 peptide could cause 
cell destruction through membranolysis through the 
same HDM-2 binding mechanism as it did in the solid 
tissue tumor cells, independent of the p53 pathway. The 
research established that the peptides are successful for 
both solid and non-solid tumors, making it a valuable drug 
that could treat a variety of cancers.
Studies and Trials on PNC-27 and PNC-28
Electron microscopy was utilized to observe the levels of 
HDM2 in the cell membrane (Wang, et al 2010). Parts of 
the membrane were isolated, and whole cell lysates from 
several different cancer and untransformed cell lines are 
shown in the figure below. The cells were blotted for 
HDM-2 (Figure 4). “In the lower section in the table, it can 
be seen that all whole cell lysates had positive results for 
the blotting procedure for HDM-2. On the upper section 
for the blots shown in the figure, the membrane fraction of 
each cancer cell line (lanes 4–7) is seen to contain signifi-
cant levels of HDM-2. In contrast, the three untransformed 
cell lines (lanes 1–3) were discovered to contain low 
levels of HDM-2 in the region22 of the membrane. The 
percentage of whole cell lysate of HDM-2 present in the 
membrane fractions of the cell lines is shown in the lower 
section of the bar graph.” (Safaraz-Yazdi E, Bownwe WB, 
2010) The graph illustrated that the fractions of HDM2 
present in the membranes of the cancer cell lines have an 
increased level of four-fold to nine-fold.
When the PNC-27 peptide was tested, researchers 
noted pain levels drop in the average time of a week. 
Three weeks following the administration of the peptide, 
the subjects sometimes developed flu-like symptoms. 
This is an indicator that the immune system had the abil-
ity to recognize and react to the death of cancer cells 
(Sookraj, Ka, Bowne WB 2010). Additionally, when the 
cancer killing peptide PNC-27 was administered after 
tumor growth had occurred at a different site from the 
original tumor, the tumor decreased in size, followed by 
a gradual increase in tumor growth that was “significantly 
slower than growth in the presence of control peptide.” If 
the cancer killing peptide is immediately senttouro to the 
tumor, researchers concluded that the peptide would be 
successful in treating cancer. (Prendergast, Jaffee, 2007). 
At six weeks, the researchers noted an increase in lactate 
dehydrogenase and bilirubin levels.
At ten weeks, a large amount of tumor breakdown is 
noticeable. At the same time, the tumors become softer 
and pliable. In addition, some increase in the size of the 
tumor itself occurred simultaneously. However, this can 
often be attributed to inflammation because of immune 
system response. At about three months, researchers 
saw that the subjects of the study exhibited better ener-
gy levels and less cancer-related symptoms.
A study published in the International Journal of Cancer 
(2006) writes that researchers discovered that PNC-28 
was able to reduce the rate of cancer cell growth in an 
organism at a quicker pace. Research tested PNC-28 to 
analyze its function to halt the replication of cancer cells. 
When PNC-28 was given over a two-week timeframe, 
the PNC-28 caused complete destruction of these tu-
mors. (Science Daily, 2006) When administered simulta-
neously with tumor implantation, PNC-28 blocked the 
tumor growth entirely in the duration of the two-week 
period of administration, as well as two weeks after treat-
ment, followed by weak tumor growth that leveled off at 
(Figure 4) “Blots of whole cell lysates (Lower) and membrane 
fractions (Upper) for H (M) DM-2 in different cell lines as follows: 
Lane 1, MCF-10-2A; lane 2, BMRPA1; lane 3, AG13145 fibroblasts; 
lane 4, TUC-3; lane 5, MIA-PaCa-2; lane 6, MCF-7; lane 7, A-2058. 
The first three cell lines are untransformed; the remainders are 
different cancer cell lines. Each bar graph shows the percentage 
of HDM-2 in whole cell lysate that is present in the membrane 
of each cell line listed above. The numbers on the X axis of the 
bar graphs correspond to the lane numbers shown in the blots.” 
(Safaraz-Yazdi E, Bownwe WB, 2010)
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low tumor size (Bowne WB, Sookraj KA, 2015). The trials 
on both drugs supported the theory that immunotherapy 
is able to eliminate cancer cells without causing damage 
to the human system.
 All methods and studies in this paper have been com-
pleted, and the drug is currently being sold out of the 
United States. It is in trial stages to be sold in the United 
States as well. PNC-27 and PNC-28 are novel drugs that 
bring much promise to the field of cancer research, and 
promises an alternative to the other harmful treatments 
being used today. However, larger studies should be con-
ducted to reduce the side effects that are experienced 
by patients taking the drug. There were no attempts in 
proving that PNC-27 is harmful for ingestion, unless 
contaminated by an outside source. There are multiple 
factors involved in creating immunotherapeutic peptides 
as treatment to cancer. Other approaches to improving 
the drug would be to further elucidate the mechanism 
by studying various models of the disease. By examining 
different models, this will hopefully give a deeper per-
spective and aid the efforts for a cure.
Conclusion
Cancer is a disease that has caused an upward trend in 
mortality rates. Although some progress has been made in 
cancer research for a cure, there are many drawbacks to 
the current treatments available. The current treatments 
are chemotherapy and radiation. While both of these treat-
ments can successfully eradicate tumors and cancer cells, 
they also tend to damage healthy cells. There is also poten-
tial for a relapse because not all cancer cells are targeted 
during treatment, as some cancer cells may drift to other 
organs and rebuild there. As a result, many cancer patients 
succumb to the toxic effects of cancer treatments rather 
than the cancer itself. With wealth of evidence in support 
of immunotherapy, this alternative treatment shows great 
promise because it does not adversely impact healthy cells. 
This is because the underlying concept of immunotherapy 
is to invest the body’s healthy cells with resources to be 
able to naturally combat the cancer cells. This is done by 
PNC-27 and PNC-28 peptides. Through research and study 
on animal subjects, the PNC-27 and PNC-28 peptides have 
been shown to be highly effective in selectively targeting 
a wide variety of specific forms of cancer, including pan-
creatic cancer, breast cancer, leukemia, melanoma, and ad-
ditional cancer lines. Since PNC-27 is non-toxic, patients 
can get rid of the cancer in a healthy manner, while aiming 
to follow a lifestyle based on holistic health and wellness. 
When properly administered, PNC-27 and PNC-28 puts 
cancer on the defensive, resulting in outcomes that include 
significant pain reduction and, in many cases, lengthening of 
life. This research supports the evidence that PNC-27 and 
PNC-28 are one of the most effective ways to treat cancer.
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